Journal
ACTA PHARMACEUTICA SINICA B
Volume 11, Issue 12, Pages 3879-3888Publisher
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.05.007
Keywords
SARS-CoV-2; Cell entry; Spike protein; Antiviral development; Post-pandemic
Categories
Funding
- Drug Innovation Major Project (China) [2018ZX09711001]
- Shandong Provincial Natural Science Foundation, China [ZR2020MH383]
- Qingdao Social Benefiting Technology Program, China [21-1-4-rkjk-15-nsh]
Ask authors/readers for more resources
This review provides an overview of SARS-CoV-2 cell entry mechanisms and the development of targeted antiviral strategies. Additionally, it speculates on future directions for the development of next-generation SARS-CoV-2 entry inhibitors in the post-pandemic era.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available